A clinical trial led by Dr. Ali Taher at the American University of Beirut Medical Center, shows that Mitapivat has potential benefits for non-transfusion dependent thalassemia patients. Developed by Agios Pharmaceuticals, Inc. Mitapivat is an oral medication that completed testing as part of the global Phase 3 ENERGIZE study – with results demonstrating improvements to anemia and quality of life for patients suffering from thalassemia. Currently, there are no approved oral therapies for both alpha- and beta-thalassemia, however the preliminary results of the Mitapivat study demonstrate a significant step towards more accessible treatments for thalassemia patients.

As an organization focused on improving the research and care of inherited blood disorders, OxyDial is eager to see the potential benefits for treatment and quality of life for patients with thalassemia worldwide.

Read more: https://aubmc.org.lb/Pages/AUBMC-leads-on-groundbreaking-research-marking-significant-advancement-in-treatment-of-thalassemia.aspx

#thalassemia #study #mitapivat #agiospharmaceuticals #ntd #thelassaemiacenter #research #phase3 #energize #medicine #hematology